Metformin and PCOS: Potential benefit to reduce miscarriage risk

Dr Daniel L Chan
MBBS (UNSW)
Intern, St George Hospital

A/Prof Gavin Sacks
MA, BM, BCh, PhD, MRCPG, CCST
Associate Professor, UNSW, Staff Specialist, St George Hospital, IVF Australia

I am writing in response to the review article by Wong (AMS Volume 2, Issue 2). [1] Polycystic ovary syndrome (PCOS) is associated with an increased risk of miscarriage, occurring in 30% of pregnancies. [2] Although the mechanism is unclear, several interrelated factors appear to increase the risk of spontaneous miscarriages, including higher luteinising hormone levels, obesity, hyperandrogenisation, insulin resistance and infertility treatments. [3]

The advantage of clomiphene citrate over metformin for induction of ovulation has been well published. However, successful achievement of pregnancy that results in miscarriage is perhaps more devastating to a patient than anovulation. The role of metformin is not restricted to its effects on infertility and ovulation alone and the potential for treatment of PCOS-related miscarriage should be acknowledged.

As medical students, we are taught to cherish randomised controlled trials and meta-analyses for their ability to eliminate potential retrospective and investigator bias. Meta-analyses [3,4] have examined the effect of metformin on miscarriage rates in PCOS patients, one as a primary outcome. [3] Both failed to demonstrate a statistically significant benefit of metformin administration on miscarriage rates. The statistical heterogeneity among the trials and authors' recommendations, that further well-designed randomised trials were required, were of concern.

The seventeen trials included in the Palomba meta-analysis [3] were scrutinised. None of the trials examined miscarriage rates as a primary outcome. Nor were they sufficiently powered to detect differences in miscarriage incidence. Metformin administration in all trials was either ceased at human chorionic gonadotropin injection or diagnosis of pregnancy. Thus meta-analyses published to date can only indicate that there is unlikely to be a reduction of miscarriage rates in PCOS patients, when metformin is administered prior to conception and ceased in early pregnancy.

This is essentially consistent with preliminary evidence which suggests, continued use for the full first trimester or throughout pregnancy [5] may reduce miscarriage risk compared with earlier cessation. To our knowledge, only non-randomised studies have evaluated the effect of metformin use during pregnancy on outcomes in PCOS patients.

A pilot study suggested continuing metformin throughout pregnancy reduced first-trimester spontaneous miscarriage without teratogenicity. [6] These findings have since been repeated in other studies, with significant reductions in first-trimester spontaneous miscarriage rates. [7]

Although these results are promising, these studies were non-randomised, often retrospective and used historical miscarriage rates, contributing to potential bias. Further large, well designed randomised controlled trials examining miscarriage rate as a primary outcome in women who continue to take metformin in the first trimester are indicated.

Recurrent miscarriage with three or more consecutive early pregnancy losses affects about one percent of the population, but the prevalence of PCOS is 40% in this population; almost eight-fold higher than in the general population. [4] However, PCOS was only given a brief mention in the updated European Society of Human Reproduction and Embryology protocol for investigation and management of recurrent miscarriage and there was no mention of metformin as a possible treatment. [8]

Since this updated protocol, a case study of a PCOS patient with recurrent miscarriage demonstrated live birth after physiologic pregnancy with metformin administration before and throughout pregnancy. [9] This indicates a possible role for metformin in the setting of PCOS patients with recurrent miscarriage and supports a need for further investigation.

As for the safety of metformin administration during pregnancy, the Australian risk category places metformin as a category C medication, indicating no evidence for any teratogenesis or adverse foetal effects, but lacks evidence to prove this definitively. Australian and long-term overseas research of metformin use in pregnant patients with diabetes mellitus or gestational diabetes mellitus demonstrates no evidence of teratogenesis. [10]

Of the studies with metformin administration during pregnancy in PCOS patients, there have been no reports of teratogenic effect. [6,7] Meta-analysis on limited data suggested no evidence of increased risk of major malformations when metformin is administered during the first trimester. [11]

In conclusion, metformin could still be an effective treatment of PCOS in the setting of miscarriage and recurrent miscarriage. Further large, well designed randomised controlled trials examining miscarriage rates in PCOS patients as a primary outcome are indicated. Metformin should be administered throughout the first trimester in these trials, consistent with promising preliminary evidence. Patients receiving metformin during pregnancy should be counselled of the risks, but can largely be reassured from the current safety evidence.

References